These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37915261)

  • 1. Editorial for "Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease".
    Reyes SC; Shahraki T; Soman S
    J Magn Reson Imaging; 2024 Aug; 60(2):548-549. PubMed ID: 37915261
    [No Abstract]   [Full Text] [Related]  

  • 2. Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease.
    Ariz M; Martínez M; Alvarez I; Fernández-Seara MA; Castellanos G; ; Pastor P; Pastor MA; Ortiz de Solórzano C
    J Magn Reson Imaging; 2024 Aug; 60(2):534-547. PubMed ID: 37915245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal assessment of nigrosomal degeneration in Parkinson's disease.
    Langley J; Huddleston DE; Crosson B; Song DD; Factor SA; Hu X
    Parkinsonism Relat Disord; 2020 Nov; 80():102-107. PubMed ID: 32979784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging evaluation of nigrosome 1 and neuromelanin can assist Parkinson's disease diagnosis, but requires an expert neuroradiologist.
    De Pietro Franco Zorzenon C; Almeida Antônio Bienes GH; Duarte Alves E; Tobaru Tibana LA; Carrete Júnior H; Ballalai Ferraz H
    Parkinsonism Relat Disord; 2021 Feb; 83():8-12. PubMed ID: 33418131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy.
    Simões RM; Castro Caldas A; Grilo J; Correia D; Guerreiro C; Pita Lobo P; Valadas A; Fabbri M; Correia Guedes L; Coelho M; Rosa MM; Ferreira JJ; Reimão S
    BMC Neurol; 2020 Nov; 20(1):432. PubMed ID: 33243166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromelanin-sensitive MRI of the substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson's disease.
    Wang J; Huang Z; Li Y; Ye F; Wang C; Zhang Y; Cheng X; Fei G; Liu K; Zeng M; Zhong C; Jin L
    Parkinsonism Relat Disord; 2019 Jan; 58():3-8. PubMed ID: 30037690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease.
    Correia Guedes L; Reimão S; Paulino P; Nunes RG; Bouça-Machado R; Abreu D; Gonçalves N; Soares T; Fabbri M; Godinho C; Pita Lobo P; Neutel D; Quadri M; Coelho M; Rosa MM; Campos J; Outeiro TF; Sampaio C; Bonifati V; Ferreira JJ
    Mov Disord; 2017 Sep; 32(9):1331-1333. PubMed ID: 28686310
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnosing Parkinson's disease by combining neuromelanin and iron imaging features using an automated midbrain template approach.
    Jokar M; Jin Z; Huang P; Wang Y; Zhang Y; Li Y; Cheng Z; Liu Y; Tang R; Shi X; Min J; Liu F; Chen S; He N; Haacke EM; Yan F
    Neuroimage; 2023 Feb; 266():119814. PubMed ID: 36528314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI).
    Nam Y; Gho SM; Kim DH; Kim EY; Lee J
    J Magn Reson Imaging; 2017 Aug; 46(2):528-536. PubMed ID: 27859983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging.
    Moon WJ; Park JY; Yun WS; Jeon JY; Moon YS; Kim H; Kwak KC; Lee JM; Han SH
    Korean J Radiol; 2016; 17(5):633-40. PubMed ID: 27587951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI T
    Lee H; Baek SY; Kim EJ; Huh GY; Lee JH; Cho H
    Neuroimage; 2020 May; 211():116625. PubMed ID: 32058001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.